¿En Español? –> Pincha Aquí

Proteolytic Enzymes and Cancer

Systemic Enzyme Therapy In Cancer Patients

  • has been subjected to
    • experimental investigations
    • rigorous clinical studies
  • results of in vitro and in vivo investigations of proteolytic enzyme mixtures (trypsin, chymotrypsin, and papain or bromelain)  → increase in these kinds of activity:
    • immunological
    • anti-inflammatory
    • anti-infectious
    • antitumor/antimetastatic
  • results of EBM level II clinical studies in patients suffering from breast and colorectal cancers and plasmacytoma
    • significantly decreases tumor-induced and therapy-induced side effects (nausea, gastrointestinal complaints, fatigue, weight loss, and restlessness)
    • stabilizes the quality of life
    • results for plasmacytoma patients
      • increases the response rates
      • increases duration of remissions
      • increases the overall survival times
  • results of previous studies of treatment of human white blood cells with proteolytic enzymes
    • production of large amounts of tumor necrosis factor in a time and dose dependent manner